NovoCure
NVCR
239 hedge funds and large institutions have $1.24B invested in NovoCure in 2025 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 100 increasing their positions, 61 reducing their positions, and 40 closing their positions.
191% more call options, than puts
Call options by funds: $16.7M | Put options by funds: $5.74M
64% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 61
10% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 40
3.26% more ownership
Funds ownership: 82.04% → 85.3% (+3.3%)
4% more capital invested
Capital invested by funds: $1.19B → $1.24B (+$50.3M)
2% less funds holding
Funds holding: 245 → 239 (-6)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$53.3M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$14.4M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$11.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.1M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$7.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$25.8M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$14.3M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$13.4M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$12.4M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$12.1M |
NVCR Hedge Fund Activity: Q4 2025 in Review
239 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q4 2025, worth a combined $1.24B — up 4.2% from $1.19B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new NVCR positions and 40 closed out — a net gain of 4 holders — while 100 added to existing stakes and 61 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $53.3M. The largest seller was Capital World Investors, exiting entirely with an estimated $25.8M sold.
- 239 institutional investors held NovoCure (NVCR) as of Q4 2025, down from 245 in Q3 2025.
- Funds reported $1.24B of NovoCure stock for Q4 2025, up 4.2% quarter-over-quarter.
- 44 funds opened new NovoCure positions in Q4 2025 and 40 closed out, a net change of +4 holders.
- The largest NovoCure buyer in Q4 2025 was Morgan Stanley, an estimated $53.3M added.
- The largest NovoCure seller in Q4 2025 was Capital World Investors, an estimated $25.8M sold.
Based on aggregated 13F filings for Q4 2025.